Exhibit 99.1

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

— Initiated URIROX-1™, First Phase 3 Trial of ALLN-177 in Enteric Hyperoxaluria; Topline Data Expected in Second Half of 2019 —

— Initiated Phase 2 Trial of ALLN-177 for Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Hyperoxalemia —

— Initiated Preclinical Proof-of-Concept Study for ALLN-346 for Patients with Hyperuricemia and Chronic Kidney Disease —

— Reiterates Guidance for Key Objectives —

NEWTON, Mass., March 27, 2018 – Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing

first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided a business update.

“In recent months, we made tremendous progress across our business, maturing Allena into a Phase 3, publicly-traded company, and advancing our pipeline of oral enzyme therapeutics for patients with severe oxalate and urate disorders,” said Alexey Margolin, Ph.D., Chief Executive Officer of Allena Pharmaceuticals. “We enter 2018 with a clear strategy for the continued development of our two first-in-class drug candidates, ALLN-177 for patients with hyperoxaluria and ALLN-346 for patients with hyperuricemia and chronic kidney disease. We look forward to executing on our key objectives in 2018, as we work to address the full spectrum of kidney-related disorders and deliver novel therapeutics for patients who are severely underserved by existing options.”

Fourth Quarter and Recent Business Highlights:

Pipeline:

ALLN-177: ALLN-177 is a first-in-class, non-absorbed, orally-administered enzyme for the treatment of severe hyperoxaluria. Allena is currently evaluating ALLN-177 in URIROX-1™, the first of two anticipated Phase 3 clinical trials designed to support a planned Biologic License Application (BLA) for ALLN-177 in patients with enteric hyperoxaluria. The Company continues to engage with the U.S. Food and Drug Administration (FDA) to finalize URIROX-2™, the second, larger planned Phase 3 clinical trial of ALLN-177 in patients with enteric hyperoxaluria, and to discuss opportunities for pursuing an accelerated approval pathway. Pending the outcome of these interactions, Allena expects to initiate URIROX-2™ in the second half of 2018. In addition, the Company is currently evaluating ALLN-177 in a Phase 2 basket trial in adolescents and adults with primary hyperoxaluria or enteric hyperoxaluria and hyperoxalemia.

 

    In March 2018, Allena initiated URIROX-1™, a multi-center, global, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate the safety and efficacy of ALLN-177 in patients with enteric hyperoxaluria. The primary endpoint of the study is percent change from baseline in 24-hour urinary oxalate (UOx) excretion averaged during Weeks 1-4, comparing ALLN-177 to placebo. Secondary endpoints include proportion of subjects with a ³20% reduction from baseline in 24-hour UOx excretion averaged during Weeks 1-4. Allena expects to announce topline data in the second half of 2019.

 

    Also in March 2018, Allena initiated Study 206, a Phase 2 basket trial to evaluate the safety and efficacy of ALLN-177 in adolescents and adults with primary hyperoxaluria or enteric hyperoxaluria and hyperoxalemia. ALLN-177 has been granted separate orphan designations for primary hyperoxaluria and pediatric hyperoxaluria by the FDA. Allena expects to announce interim data from Study 206 in the second half of 2018.

 

    In November 2017, Allena presented final results from its Phase 2 clinical trials of ALLN-177 in patients with secondary hyperoxaluria at the American Society of Nephrology (ASN) Kidney Week 2017 in New Orleans, LA. In patients with enteric disease, ALLN-177 substantially reduced UOx and was well-tolerated. Also at ASN, Allena presented preclinical data from a porcine dietary model of severe hyperoxaluria, which showed a significant reduction in both plasma oxalate and UOx excretion.


The following information was filed by Allena Pharmaceuticals, Inc. (ALNA) on Tuesday, March 27, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Allena Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allena Pharmaceuticals, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account